01803nam a2200361Ia 4500001000700000003000600007005001700013006001900030007001500049008004100064020001500105037002000120040001300140043001200153074001100165074002000176074001100196074002000207086002900227110009900256245050200355260008000857300003000937490002800967500008600995500006001081500003201141504004101173530004201214650005901256650006801315810005801383265932OCoLC20160527193412.0m        d f      cr mnu---uuaun040505s2004    dcua    sb   f000 0 eng d  a0160715229  a552-070-31093-2  aBUFcBUF  an-us---  a1043-A  a1043-A (online)  a1043-B  a1043-B (online)0 aY 4.L 11/4:S.HRG.108-3781 aUnited StatesbCongress.bSenate.bCommittee on Health, Education, Labor, and Pensions.2Local10aFederal and state role in pharmacy compounding and reconstitutionbexploring the right mix to protect patients : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, first session, on examining state and federal oversight to ensure the safety and quality of drug compounding--the process of mixing, combining, or altering ingredients to create a customized medication for an individual patient--by pharmacies, October 23, 2003.  aWashingtonbU.S. G.P.O.bFor sale by the Supt. of Docs., U.S. G.P.O.c2004.  aiii, 145 p.bill.c24 cm.1 aS. hrg.v108-3782Local  a"Printed for the use of the Committee on Health, Education, Labor, and Pensions."  aDistributed to some depository libraries in microfiche.  aTitle from resource itself.  aIncludes bibliographical references.  aAlso available via the World Wide Web 0aDrugsxDosage formszUnited StatesxEvaluation.2Local 0aPharmaceutical IndustryzUnited StatesxQuality control.2Local1 aUnited States.bCongress.bSenate.tS. hrg.v108-378.